On this page
Yuflyma
adalimumab-aaty
351(k) Interchangeable Pharmacy-substitutable
Overview
Source: Purple BookProprietary name
Yuflyma
Proper name
adalimumab-aaty
Licence type
351(k) Interchangeable
BLA number
761219
Applicant
CELLTRION, Inc.
Center
CDER
Presentations
6
First licensure
—
351(k) biosimilar pathway. This product was licensed as highly
similar to a reference product, with no clinically meaningful differences in
safety, purity or potency.
It also carries the interchangeable designation, so a pharmacist may substitute it for the reference product without contacting the prescriber.
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 10MG/0.1ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | October 28, 2025 |
| 20MG/0.2ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | September 29, 2023 |
| 40MG/0.4ML | Injection | Subcutaneous | Autoinjector | Rx | May 23, 2023 |
| 40MG/0.4ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | May 23, 2023 |
| 80MG/0.8ML | Injection | Subcutaneous | Autoinjector | Rx | September 29, 2023 |
| 80MG/0.8ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | September 29, 2023 |
Reference product
Source: Purple BookThis product is licensed with reference to Humira (adalimumab).
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |